Hypogammaglobulinemia, a new risk factor for hepatitis B virus reactivation : about two cases.
(2023) Acta Gastro-Enterologica Belgica — Vol. 86, n° 3, p. 493-494 (2023)
Files
deLeuze2023.pdf
Open Access - Adobe PDF
- 192.72 KB
Details
- Authors
- Abstract
- Reactivation of the hepatitis B virus (HBV) with immunosuppressive status has been well established, mainly due to medications such as immunosuppressive therapy like cytotoxic chemotherapy, rituximab and biologic therapy, immunosuppression after solid and bone-marrow transplantation or long-term corticosteroids therapy. We report here two cases of HBV reactivation due to global hypogammaglobulinemia. Regular HBV serologic screening and PCR for HBV-DNA should be applied for each patient with primary immunosuppressive status and history of chronic HBV infection. The necessity of a preemptive treatment remains debated.
- Affiliations
Citations
de Leuze, F., Havelange, V., van Dievoet, M.-A., Horsmans, Y., & Dahlqvist, G. (2023). Hypogammaglobulinemia, a new risk factor for hepatitis B virus reactivation : about two cases. Acta Gastro-Enterologica Belgica, 86(3), 493-494. https://doi.org/10.51821/86.3.10755 (Original work published 2023)